IMPORTANT SAFETY INFORMATION: Myrbetriq is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet.

Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg).

Please see additional Important Safety Information below.

For your patients with overactive bladder (OAB)

Rethinq OAB Treatment

MYRBETRIQ is a β3-adrenergic agonist indicated for patients with OAB symptoms of urge urinary incontinence, urgency, and urinary frequency1

It may be time to take another look at OAB treatment with MYRBETRIQ

Clinical trial data

MYRBETRIQ 25mg and 50mg were randomized in 3 clinical trials in patients with OAB symptoms of urge urinary incontinence, urgency, and urinary frequency

See study data

Access for your patients

MYRBETRIQ is covered for 85% of lives on Commercial plans2*†



Learn more

*Not a guarantee of coverage. Please verify coverage and updated information with the plan sponsors. Information subject to change without notice.

By total Commercial covered lives (162,655,877); Plan types: Commerical, Commercial (BCBS), Employer, HIX, PBM, Union. Source: Fingertip Formulary, as of July 2015.